Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a fixed-dose combination product containing gamma-aminobutyric acid (GABA) tartarate, glutamic acid, dibasic calcium phosphate (as a source of calcium), thiamine nitrate (vitamin B1), pyridoxine chloride (vitamin B6), and cyanocobalamin (vitamin B12). The combination is designed to address neurological symptoms and support nervous system health. GABA acts as an inhibitory neurotransmitter in the central nervous system, while glutamic acid serves as an excitatory neurotransmitter. Calcium supports neuronal function. Thiamine, pyridoxine, and cyanocobalamin are essential B vitamins involved in nerve metabolism, myelin synthesis, and cellular energy production. This combination has been studied for the management of chronic complaints consistent with motion sickness and has shown efficacy in reducing symptoms compared to ginger extract[1][2]. The components also have established roles in treating or preventing vitamin deficiencies and supporting nerve health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gamma-aminobutyric acid tartarate + glutamic acid + dibasic calcium phosphate + thiamine nitrate + pyridoxine chloride + cyanocobalamin.